An overview of glioblastoma multiforme and temozolomide resistance

Glioblastoma multiforme (GBM) is a primary type of lethal brain tumor. Over the last two decades, temozolomide (TMZ) has remained the ...

Temozolomide resistance in glioblastoma multiforme - ScienceDirect

This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell ...

Temozolomide resistance in glioblastoma multiforme

787 Citations · Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell Lines · Mechanisms of temozolomide ...

Dissecting the mechanism of temozolomide resistance and its ...

Glioblastoma is the most common primary malignant brain tumor that is usually considered fatal even with treatment. This is often a result ...

Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme ...

Temozolomide demonstrates relatively good efficacy in therapy, but it could also present with several side effects. The resistance of GBM to the drug is ...

[PDF] Mechanisms of temozolomide resistance in glioblastoma

This review aims to provide a comprehensive overview of the clinically relevant molecular mechanisms and their extensive interconnections to better inform ...

Temozolomide resistance in glioblastoma multiforme

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ ...

Overcoming Resistance to Temozolomide in Glioblastoma - MDPI

In this review, preclinical and clinical data about temozolomide resistance acquisition and possible ways to overcome chemoresistance, or to treat gliomas

Molecular mechanisms of temozolomide resistance in glioblastoma ...

Glioblastoma multiforme (GBM; WHO astrocytoma grade IV) is the most common and most malignant primary brain tumor in adults. It grows rapidly ...

Elucidating the mechanisms of Temozolomide resistance in gliomas ...

Temozolomide (TMZ) is a first-choice alkylating agent inducted as a gold standard therapy for glioblastoma multiforme (GBM) and astrocytoma.

Temozolomide resistance in glioblastoma multiforme - SciOpen

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ ...

Temozolomide resistance in glioblastoma cells occurs partly through ...

Glioblastoma Multiforme (GBM) is an aggressive adult primary brain tumor with poor prognosis. GBM patients develop resistance to the ...

e1431-Novel-approaches-to-reduce-temozolomide-resistance-in ...

In the present review, an overview of the recent works on the ... KEYWORDS: Temozolomide, Glioblastoma multiforme, Drug resistance, Alkylating agents, O6.

A Potential Mechanism of Temozolomide Resistance in Glioma ...

Studies have shown that glioma TMZ resistance is a complex process with multiple factors, which has not been fully elucidated. Ferroptosis, ...

Mechanisms of temozolomide resistance in glioblastoma

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an exceedingly low median overall survival of only 15 months.

Potential Strategies Overcoming the Temozolomide Resistance for ...

Glioblastoma (GBM) is a highly malignant type of primary brain tumor with a high mortality rate. Although the current standard therapy consists of surgery ...

Glioblastoma Multiforme (GBM): An overview of current therapies ...

This multimodality regimen used for glioblastomas is consistently associated with a poor prognosis, mainly due to the inherent resistance of the ...

Induction of MGMT expression is associated with temozolomide ...

Temozolomide (TMZ)-based therapy is the standard of care for patients with glioblastoma multiforme (GBM), and resistance to this drug in GBM is modulated by the ...

Temozolomide Resistance in Glioblastoma Multiforme - Iris Publishers

Glioblastoma multiforme (GBM) is the most common and malignant type of brain cancer. Current standard therapy for GBM involves surgery ...

Alkylpurine–DNA–N-glycosylase confers resistance to ... - JCI

Glioblastoma multiforme (GBM) is the most common and lethal of all gliomas. The current standard of care includes surgery followed by ...